10x Genomics Inc (NASDAQ: TXG): Reassessing Prospects

10x Genomics Inc (TXG) concluded trading on Thursday at a closing price of $7.70, with 3.91 million shares of worth about $30.13 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -61.71% during that period and on April 10, 2025 the price saw a loss of about -11.19%. Currently the company’s common shares owned by public are about 108.24M shares, out of which, 100.79M shares are available for trading.

Stock saw a price change of -3.39% in past 5 days and over the past one month there was a price change of -29.03%. Year-to-date (YTD), TXG shares are showing a performance of -46.38% which decreased to -79.40% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $6.78 but also hit the highest price of $36.46 during that period. The average intraday trading volume for 10x Genomics Inc shares is 3.03 million. The stock is currently trading -15.99% below its 20-day simple moving average (SMA20), while that difference is down -29.32% for SMA50 and it goes to -52.35% lower than SMA200.

10x Genomics Inc (NASDAQ: TXG) currently have 108.24M outstanding shares and institutions hold larger chunk of about 83.15% of that.

The stock has a current market capitalization of $941.73M and its 3Y-monthly beta is at 1.91. It has posted earnings per share of -$1.52 in the same period. It has Quick Ratio of 4.26 while making debt-to-equity ratio of 0.12. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for TXG, volatility over the week remained 15.96% while standing at 8.20% over the month.

Stock’s fiscal year EPS is expected to drop by -0.01% while it is estimated to increase by 22.06% in next year. EPS is likely to grow at an annualized rate of 15.93% for next 5-years, compared to annual growth of -36.10% made by the stock over the past 5-years.

Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Leerink Partners on February 13, 2025 offering a Market perform rating for the stock and assigned a target price range of between $25 and $12 to it. Coverage by Leerink Partners stated 10x Genomics Inc (TXG) stock as an Outperform in their note to investors on September 03, 2024, suggesting a price target of $35 for the stock. On July 22, 2024, Jefferies Upgrade their recommendations, while on July 18, 2024, JP Morgan Downgrade their ratings for the stock with a price target of $20. Stock get a Hold rating from Deutsche Bank on July 10, 2024.

Related Posts

Life Telegraph
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.